ECRFPlus Secures Tens of Millions in Strategic Funding to Accelerate the Industrialization of Its 3Q Digital Clinical Trial Platform

VCBeat has learned that Hangzhou Yikefu Technology Co., Ltd., the earliest domestic company focused on digital clinical trial information technology, has completed a strategic financing round worth tens of millions of yuan. This round was exclusively invested by Liangyihui, China's largest professional academic platform for cancer treatment. It is reported that the funds will be used to accelerate the industrialization of the company’s 3Q Digital Clinical Service Platform.

Yikefu Technology is a company based onAn IT Services Company for Digital Clinical Research Leveraging “Internet+” Technologies, focusing on providingSponsors, clinical research centers, national regulatory authorities, and third-party providers offer professional information technology solutions and clinical acceleration services.

Founder: Lu MinMr. [Name] has been dedicated to the field of clinical trial informatization for over two decades,2002CreatedYikefu, USA, and on2006Established with advanced technologies and concepts from global clinical research,Hangzhou Yikefu Technology Co.,Ltd.。

Yikefu has independently developed a series of products with Chinese characteristics3Q Digital Clinical Trial Integrated Solution,Serving drug R&D institutions, CROs, and clinical research centers in Europe, the United States, and China, andBeijing, Shanghai, Guangzhou, Hangzhou, Wuhan, Chengduand other regions, establishing a nationwide technical service center. In the pastOver a decadeforOver 100Tertiary HospitalProvided an integrated platform solution for clinical research and participated in the construction of the clinical evaluation technology platforms for major new drug development under the National Ministry of Science and Technology’s 12th and 13th Five-Year Plans at multiple hospitals.

Mr. Wang Jue, Founder and CEO of Liangyihui“Liangyihui, as a platform serving oncologists, covers over 200,000 oncologists in China, providing comprehensive services across medical practice, education, and research to enhance the digitalization level and efficiency of the industry. It is well known that there is strong demand among oncologists and enterprises for conducting clinical trials and launching new drugs. Liangyihui has been actively seeking high-quality partners to accelerate the digitalization of clinical trials, thereby offering more comprehensive services to clinicians. Since its establishment, Hangzhou Yikefu Technology Co., Ltd. (Yikefu) has been committed to advancing the digitalization of clinical research, helping physicians expedite clinical trials, and has accumulated extensive experience. Liangyihui is fortunate to partner with Yikefu, combining Liangyihui’s physician resources with Yikefu’s years of technological expertise. This collaboration aims to better help clinicians improve the efficiency of clinical research, facilitate the rapid market launch of new drugs, reduce upfront costs, and jointly promote the digital transformation of clinical research in China.”

Mr. Lu Min, Founder and CEO of Yikefu“Yikefu, a pioneer in electronic clinical technology, has remained dedicated to the research and development of such technologies over the past fifteen years. It has developed the ‘3Q Electronic Clinical Solution,’ tailored to the Chinese context, which addresses key challenges associated with traditional EDC and CTMS systems—such as reliance on manual data acquisition from hospitals and data silos. This innovative, comprehensive solution helps shorten clinical study cycles by 30%–60%. We are delighted that Yikefu’s 3Q electronic clinical technology has received strong recognition from Liangyihui (MedCircle). Leveraging Liangyihui’s strategic investment and its resource advantages in serving global pharmaceutical companies and hundreds of thousands of physicians will accelerate the adoption and promotion of Yikefu’s 3Q electronic clinical trial technology among sponsors, CROs, and hospitals, thereby driving the second technological revolution toward full-process digitalization in clinical trials.”

It is reported that R&D investment in China’s pharmaceutical industry grew from USD 10.5 billion in 2015 to USD 21.1 billion in 2019, representing a compound annual growth rate (CAGR) of 19.1%, and is projected to reach USD 47.6 billion by 2024.

Amidst the vast blue ocean market, leveraging digital technologies to empower and accelerate drug clinical research has evolved from a basic necessity into an urgent imperative.

Currently, Hangzhou Yikefu Technology Co., Ltd. has partnered with global CRO giantsIQVIAEstablish a long-term strategic partnership withDozens ofChina’s top clinical research hospitals, including West China Hospital of Sichuan University and Fudan University Shanghai Cancer Center, have engaged in deep collaboration. With the launch of a new round of financing, Hangzhou Yikefu Technology Co., Ltd. has comprehensively upgraded its strategy to further accelerate its industry layout and become a leader in clinical digitalization technologies.

Liangyi Hui is a leading digital oncology patient-physician service platform in China. It maintains long-term, effective, and in-depth collaborations with many renowned domestic and international hospitals and authoritative institutions, dedicated to advancing the internetization and digitalization of oncology healthcare and pharmaceuticals, thereby enhancing efficiency within the oncology industry.